XNASHLVX
Market cap93mUSD
Dec 24, Last price
1.87USD
1D
0.54%
1Q
6.25%
IPO
-90.68%
Name
Hillevax Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-124m
L-51.92%
CFO
-87m
L+40.00%
Profile
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 135,501 | 64,865 | 15,773 | ||
Unusual Expense (Income) | |||||
NOPBT | (135,501) | (64,865) | (15,773) | ||
NOPBT Margin | |||||
Operating Taxes | 97,196 | (17,383) | |||
Tax Rate | |||||
NOPAT | (135,501) | (162,061) | 1,610 | ||
Net income | (123,566) -51.92% | (257,005) 202.27% | (85,025) 3,888.04% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 108,898 | 230,006 | 1,000 | ||
BB yield | -16.71% | -36.51% | |||
| Debt | |||||
Debt current | 6,236 | 37 | 158,308 | ||
Long-term debt | 74,024 | 57,967 | 338 | ||
Deferred revenue | |||||
Other long-term liabilities | 1,568 | 575 | 1,000 | ||
Net debt | (223,223) | (223,028) | 34,080 | ||
| Cash flow | |||||
Cash from operating activities | (86,783) | (61,989) | (7,295) | ||
CAPEX | (10,748) | (6,514) | (2,808) | ||
Cash from investing activities | (94,638) | (6,514) | (2,808) | ||
Cash from financing activities | 118,698 | 224,969 | 134,212 | ||
FCF | (142,656) | (186,775) | 1,379 | ||
| Balance | |||||
Cash | 303,483 | 279,401 | 124,566 | ||
Long term investments | 1,631 | ||||
Excess cash | 303,483 | 281,032 | 124,566 | ||
Stockholders' equity | (389,461) | (265,270) | (105,183) | ||
Invested Capital | 710,865 | 569,472 | 162,888 | ||
ROIC | 1.94% | ||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 40,598 | 37,656 | 30,191 | ||
Price | 16.05 -4.06% | 16.73 | |||
Market cap | 651,606 3.43% | 629,985 | |||
EV | 428,383 | 406,957 | |||
EBITDA | (133,345) | (64,864) | (15,770) | ||
EV/EBITDA | |||||
Interest | 2,392 | 3,414 | 2,844 | ||
Interest/NOPBT | |||||